Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of HIP2001 vs HGP2001 in Healthy Volunteers
NCT04764201Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jan 2021
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of edoxaban in Atrial fibrillation (AFib) (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to the Last Measurable Concentration and Maximum Plasma Concentration. Started Jan 2021; status: completed.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04764201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04764201.